J&J’s experimental Sjögren's treatment shows greater impact in key patient subgroup
Johnson & Johnson (NYSE:JNJ) disclosed new data on Wednesday showing its experimental autoimmune treatment, nipocalimab, yields stronger clinical results in patients with higher concentrations of specific disease-driving biomarkers.










